OrbiMed
Jan 10, 2019
Apollomics raises; Pear Therapeutics raises $64M; Lilly to acquire Loxo
Apollomics raises USD 100 Million for funding of transpacific cancer R&D plan Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor and pipeline of other clinical-phase assets. OrbiMed Asia-backed Apo...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
